Venous thromboembolic disease.
Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.
Michael B
MB
Streiff
Paula L
PL
Bockenstedt
Spero R
SR
Cataland
Carolyn
C
Chesney
Charles
C
Eby
John
J
Fanikos
Annemarie E
AE
Fogerty
Shuwei
S
Gao
Samuel Z
SZ
Goldhaber
Hani
H
Hassoun
Paul
P
Hendrie
Bjorn
B
Holmstrom
Nicole
N
Kuderer
Jason T
JT
Lee
Michael M
MM
Millenson
Anne T
AT
Neff
Thomas L
TL
Ortel
Tanya
T
Siddiqi
Judy L
JL
Smith
Gary C
GC
Yee
Anaadriana
A
Zakarija
Nicole
N
McMillian
Maoko
M
Naganuma
D000925:Anticoagulants / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D011292:Premedication; D018570:Risk Assessment; D054556:Venous Thromboembolism / Q000188:drug therapy* / Q000209:etiology* / Q000517:prevention & control
D000925:Anticoagulants